Checchi Capital Advisers LLC Increases Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Checchi Capital Advisers LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 10,565 shares of the biopharmaceutical company’s stock after purchasing an additional 297 shares during the quarter. Checchi Capital Advisers LLC’s holdings in Gilead Sciences were worth $976,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. State Street Corp grew its holdings in Gilead Sciences by 1.4% in the third quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company’s stock worth $5,044,795,000 after purchasing an additional 841,776 shares during the period. Wellington Management Group LLP grew its holdings in Gilead Sciences by 50.9% in the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after purchasing an additional 11,665,593 shares during the period. FMR LLC lifted its stake in shares of Gilead Sciences by 79.4% in the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock worth $2,780,329,000 after buying an additional 14,680,161 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Gilead Sciences by 2.1% in the third quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company’s stock worth $2,302,119,000 after buying an additional 574,421 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Gilead Sciences by 3.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 7,752,975 shares of the biopharmaceutical company’s stock worth $650,009,000 after buying an additional 224,960 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $104.09, for a total transaction of $260,225.00. Following the completion of the transaction, the chief financial officer now owns 169,061 shares in the company, valued at $17,597,559.49. This trade represents a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders sold 542,001 shares of company stock valued at $52,230,551. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $110.46 on Thursday. The firm has a fifty day moving average price of $96.56 and a 200-day moving average price of $89.49. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The stock has a market cap of $137.66 billion, a PE ratio of 298.54, a price-to-earnings-growth ratio of 0.71 and a beta of 0.18. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $112.11.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.86%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 854.05%.

Analyst Ratings Changes

Several research analysts have recently issued reports on GILD shares. Cantor Fitzgerald reiterated a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a research note on Wednesday, December 11th. Piper Sandler upped their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 12th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. UBS Group upped their target price on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a research note on Thursday, November 21st. Finally, Wells Fargo & Company upped their target price on shares of Gilead Sciences from $105.00 to $120.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $102.08.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.